$INO: Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
$167,000,000 In Cash.....Strong Intellectual Property With Over 200 Patents.....Multiple Serious Catalysts Including INO 5401/Regeneron's Libtayo For GBM/BrainCancer Phase 3 Looming Large.....INO 4201 Ebola Booster Potential Partnership Update.....INO 3107 Commercialization/BLA Update For RRP Including Europe Where INO 3107 Has Orphan Drug Status....In China Advaccine With INO 4800/4802 Covid 19 Vaccine/Booster.....Also In China VGX 3100 With ApolloBio Now In Phase 3 Commercialization News Coming In China.....See Pipeline On INOVIO Website....Analyst Upgrades etc!.....IMHO These Are Likely Milestones That Will Be Achieved
